David Ricks to head Eli Lilly, as John Lechleiter is set to retire

27 July 2016

US pharma major Eli Lilly (NYSE: LLY) is to have an new president and chief executive effective next year, as incumbent John Lechleiter is to retire at the end of 2016, the company has announced.

This is the second CEO departure for a leading drugmaker announced in the past week, following the announcement that George Scangos is to step down as the chief executive of US biotech major Biogen in the coming months after a successor has been identified.

Lilly's board of directors unanimously elected David Ricks, currently senior vice president and president, Lilly Bio-Medicines, to assume the role of president and chief executive officer and to join the board on January 1, 2017, and to become chairman of the board on June 1, 2017. 63 year-old Dr Lechleiter , who has been the company's CEO since April 1, 2008 having joined the company in 1979, will continue on Lilly's board of directors until May 31, 2017, serving as non-executive chairman, at which time he will leave the board. A successor as president of Lilly Bio-Medicines will be announced at a later date.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK